AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2465533 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous morphine infusion (5-48 mg, median 19 mg daily)
Number of subjects: 36
Study 2465533 — intervention group
Group type: COMPARATOR
Intervention: Conventional intermittent oral or subcutaneous morphine application (10-90 mg, median 50 mg daily)
Number of subjects: 36
Study 2465533 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous morphine infusion
Number of subjects: 36
Study 2465533 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term continuous subcutaneous morphine infusion
Number of subjects: 36
Study 30036893 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympus Exera III, 190 colonoscopes (190-C)
Number of subjects: 1221
Study 30036893 — intervention group
Group type: COMPARATOR
Intervention: Olympus 165 colonoscopes (165-C)
Number of subjects: 1221
Study 28185141 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart (0.2 U/kg) administered subcutaneously in the abdomen
Number of subjects: 21
Study 28185141 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart (0.2 U/kg) administered subcutaneously in the upper arm
Number of subjects: 21
Study 28185141 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart (0.2 U/kg) administered subcutaneously in the thigh
Number of subjects: 21
Study 28185141 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart (0.02 U/kg) administered intravenously
Number of subjects: 21
Study 26198807 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide plus weight management
Number of subjects: 89
Study 26198807 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 89
Study 26198807 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus weight management
Number of subjects: 89
Study 26198807 — intervention group
Group type: EXPERIMENTAL
Intervention: RGCL thickness less than the fifth percentile of controls
Number of subjects: 89
Study 23047989 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (15 mg/kg [160 mg/mL])
Number of subjects: 63
Study 23047989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (volume-matched)
Number of subjects: 63
Study 21778605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding agent
Number of subjects: 0
Study 21778605 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone
Number of subjects: 0
Study 21778605 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone+Bonding agent
Number of subjects: 0
Study 21778605 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane
Number of subjects: 0
Study 21778605 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane+Bonding agent
Number of subjects: 0
Study 21778605 — intervention group
Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 0
Study 19454872 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Strategy Questionnaire-Revised (CSQ-R)
Number of subjects: 442
Study 16426088 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant exposure (initiation or dose increase)
Number of subjects: 425
Study 16426088 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant exposure (initiation)
Number of subjects: 425
Study 16426088 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism, prior attempt, and higher depressive or manic symptom ratings
Number of subjects: 425
Study 16426088 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased antidepressant exposure
Number of subjects: 425
Study 16426088 — intervention group
Group type: COMPARATOR
Intervention: Control for empirically identified confound
Number of subjects: 425
Study 15010373 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon-alfa (5 MIU/m(2) daily)
Number of subjects: 407
Study 15010373 — intervention group
Group type: COMPARATOR
Intervention: Low-dose interferon-alfa (3 MIU, 5 times a week)
Number of subjects: 407
Study 15010373 — intervention group
Group type: COMPARATOR
Intervention: Quality of life data
Number of subjects: 407
Study 11768817 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective contact isolation (isolation group) with disposable gowns and nonsterile gloves; handwashing required before entry and on leaving the room.
Number of subjects: 0
Study 11768817 — intervention group
Group type: COMPARATOR
Intervention: Standard precautions (control group) with handwashing and nonsterile gloves.
Number of subjects: 0
Study 9139661 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug treatment with viral protease and reverse transcriptase inhibitors
Number of subjects: 0
Study 1662579 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C, thiopronine, and glutathione at a dose of 12 mmol
Number of subjects: 0
Study 1662579 — intervention group
Group type: COMPARATOR
Intervention: Healthy normal subjects
Number of subjects: 0
Study 7037156 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with methyl‐CCNU and 5‐FU
Number of subjects: 142
Study 7037156 — intervention group
Group type: COMPARATOR
Intervention: Control (no chemotherapy)
Number of subjects: 142
Study 31496331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐consultation information on planned consultation time
Number of subjects: 0
Study 31496331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre‐consultation information)
Number of subjects: 0
Study 31496331 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed physicians
Number of subjects: 0
Study 28254561 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE immunoadsorption with IgEnio
Number of subjects: 15
Study 28254561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 27502857 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (n = 179)
Number of subjects: 360
Study 27502857 — intervention group
Group type: COMPARATOR
Intervention: No-colchicine (n = 181)
Number of subjects: 360
Study 22452364 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation (BA) training
Number of subjects: 10
Study 22452364 — intervention group
Group type: COMPARATOR
Intervention: Behavioural activation (BA)
Number of subjects: 10
Study 21383095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine (DP)
Number of subjects: 292
Study 21383095 — intervention group
Group type: COMPARATOR
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 292
Study 21383095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine (DP) without trimethoprim‐sulfamethoxazole prophylaxis (TS)
Number of subjects: 292
Study 18614568 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive vision and eye examinations conducted by an optometrist
Number of subjects: 616
Study 18614568 — intervention group
Group type: COMPARATOR
Intervention: No vision assessment or intervention
Number of subjects: 616
Study 17097955 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg once daily)
Number of subjects: 115
Study 17097955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 14742344 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H (hypnotic anaesthesia) with propofol effect-site concentration maintained at 2.4 microg x ml(‐1)
Number of subjects: 46
Study 14742344 — intervention group
Group type: COMPARATOR
Intervention: Group O (opioid anaesthesia) with propofol effect-site concentration maintained at 1.2 microg x ml(‐1)
Number of subjects: 46
Study 11356779 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg im weekly)
Number of subjects: 54
Study 11356779 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 54
Study 11356779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11356779 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 54
Study 9578508 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment at a dose of 9.5 microg/kg, administered subcutaneously every evening
Number of subjects: 30
Study 9578508 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 7802237 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 30
Study 7802237 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 30
Study 7802237 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 30
Study 3376143 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide
Number of subjects: 15
Study 3376143 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide
Number of subjects: 15
Study 30151225 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational curriculum enhanced with diet and physical activity components
Number of subjects: 54
Study 30151225 — intervention group
Group type: COMPARATOR
Intervention: Standard educational curriculum (control)
Number of subjects: 54
Study 28944722 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength‐training programme (full‐back squat, YoYoTM leg curl, plyometrics and sled towing exercises) performed 1 day per week (EXP1)
Number of subjects: 36
Study 28944722 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength‐training programme (full‐back squat, YoYoTM leg curl, plyometrics and sled towing exercises) performed 2 days per week (EXP2)
Number of subjects: 36
Study 28944722 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 36
Study 26166187 — intervention group
Group type: EXPERIMENTAL
Intervention: Safewards model interventions
Number of subjects: 31
Study 23948125 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily for 24 weeks
Number of subjects: 241
Study 23948125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 23948125 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 241
Study 21393647 — intervention group
Group type: EXPERIMENTAL
Intervention: Saunders traction
Number of subjects: 45
Study 21393647 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) and traction
Number of subjects: 45
Study 21393647 — intervention group
Group type: COMPARATOR
Intervention: TENS only
Number of subjects: 45
Study 19070211 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-conformal radiotherapy (3D-CRT) with 80 Gy in 40 fractions over 8 weeks (arm A)
Number of subjects: 69
Study 19070211 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-conformal radiotherapy (3D-CRT) with 62 Gy in 20 fractions over 5 weeks (arm B)
Number of subjects: 69
Study 19070211 — intervention group
Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 69
Study 17023701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterol Bev (orange juice with 1 g plant sterols per 240 mL, twice a day for 8 weeks)
Number of subjects: 72
Study 17023701 — intervention group
Group type: COMPARATOR
Intervention: Placebo Bev (reduced-calorie orange juice without plant sterols, twice a day for 8 weeks)
Number of subjects: 72
Study 15124555 — intervention group
Group type: EXPERIMENTAL
Intervention: MammoSite per-operative brachytherapy technique
Number of subjects: 0
Study 15124555 — intervention group
Group type: COMPARATOR
Intervention: Standard whole breast irradiation followed by a tumor bed booster dose
Number of subjects: 0
Study 10952094 — intervention group
Group type: COMPARATOR
Intervention: 1 mg isoflavones/kg body weight/day (65 mg/day)
Number of subjects: 18
Study 10952094 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg isoflavones/kg body weight/day (132 mg/day)
Number of subjects: 18
Study 10952094 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg isoflavones/kg body weight/day (control diet)
Number of subjects: 18
Study 8777833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (60 kJ per kg of body weight)
Number of subjects: 0
Study 8777833 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (60 kJ per kg of body weight)
Number of subjects: 0
Study 8777833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat meal (60 kJ per kg of body weight)
Number of subjects: 0
Study 8777833 — intervention group
Group type: COMPARATOR
Intervention: Control meal (water)
Number of subjects: 0
Study 8420693 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin, MPH)
Number of subjects: 0
Study 8420693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (Depakene, VPA)
Number of subjects: 0
Study 8420693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10315745 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention (nurse counseling and printed materials)
Number of subjects: 230
Study 10315745 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 230
Study 29800546 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (oral omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for a week)
Number of subjects: 898
Study 29800546 — intervention group
Group type: COMPARATOR
Intervention: No H pylori treatment (control group)
Number of subjects: 898
Study 29800546 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 898
Study 27881086 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-based unstable resistance training (M-URT)
Number of subjects: 75
Study 27881086 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-weight unstable resistance training (F-URT)
Number of subjects: 75
Study 27881086 — intervention group
Group type: COMPARATOR
Intervention: Machine-based stable resistance training (M-SRT)
Number of subjects: 75
Study 27881086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity resistance training on even and uneven surfaces
Number of subjects: 75
Study 24491077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 63
Study 24491077 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Behavior Family Therapy (SBFT)
Number of subjects: 63
Study 24491077 — intervention group
Group type: COMPARATOR
Intervention: Nondirective Supportive Therapy (NST)
Number of subjects: 63
Study 24130463 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (10 IU) injected one minute after birth
Number of subjects: 1586
Study 24130463 — intervention group
Group type: COMPARATOR
Intervention: Control (no provision of prophylactic oxytocin)
Number of subjects: 1586
Study 21443815 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose DHA (approximately 1 % dietary fatty acids)
Number of subjects: 657
Study 21443815 — intervention group
Group type: COMPARATOR
Intervention: Standard DHA (0.2-0.3 % DHA)
Number of subjects: 657
Study 21443815 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose DHA
Number of subjects: 657
Study 18343794 — intervention group
Group type: EXPERIMENTAL
Intervention: PCHR-based health promotion program
Number of subjects: 76
Study 18343794 — intervention group
Group type: COMPARATOR
Intervention: Control group (received messages addressing cardiovascular health and sun protection)
Number of subjects: 76
Study 17190110 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (200 mg/d ellagic acid)
Number of subjects: 39
Study 17190110 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (100 mg/d ellagic acid)
Number of subjects: 39
Study 17190110 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg/d ellagic acid: placebo)
Number of subjects: 39
Study 14598411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 442
Study 14598411 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 442
Study 11051347 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 2 weeks
Number of subjects: 471
Study 11051347 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 471
Study 8719186 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stimulation (skin incision) in groups 1 and 3 (each n = 20)
Number of subjects: 60
Study 8719186 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion (0.1 microgram.kg‐1.min‐1) in groups 2 and 4 (each n = 10)
Number of subjects: 60
Study 1463996 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium, vitamins A, C, E and selenium (in a cocktail)
Number of subjects: 116
Study 1463996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 6367888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (2g) plus probenecid (1g)
Number of subjects: 201
Study 6367888 — intervention group
Group type: COMPARATOR
Intervention: Sulphamethoxazole‐trimethoprim (SMX‐TMP) (sulphamethoxazole 1600 mg plus trimethoprim 320 mg) four tablets twice daily for two days
Number of subjects: 201
Study 6367888 — intervention group
Group type: COMPARATOR
Intervention: Sulphamethoxazole‐trimethoprim (SMX‐TMP)
Number of subjects: 201
Study 31055791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (1.4 ± 0.5 g/day, as mycophenolate mofetil)
Number of subjects: 27
Study 31055791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (5 ± 3 mg/day, immediate release)
Number of subjects: 27
Study 28950421 — intervention group
Group type: EXPERIMENTAL
Intervention: SB5 (adalimumab biosimilar)
Number of subjects: 544
Study 28950421 — intervention group
Group type: COMPARATOR
Intervention: Reference Adalimumab (ADA)
Number of subjects: 544
Study 26083426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral maxillary block (group M)
Number of subjects: 40
Study 26083426 — intervention group
Group type: COMPARATOR
Intervention: Scalp block (group S)
Number of subjects: 40
Study 24639106 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol (1 mg loading dose followed by 48-h infusion of 0.004 % butorphanol with 0.1 % bupivacaine at 2 mL/h)
Number of subjects: 83
Study 24639106 — intervention group
Group type: COMPARATOR
Intervention: Normal saline combined with bupivacaine (saline loading dose and 0.1 % bupivacaine infusion at 2 mL/h)
Number of subjects: 83
Study 24639106 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol
Number of subjects: 83
Study 24639106 — intervention group
Group type: COMPARATOR
Intervention: Normal saline combined with bupivacaine
Number of subjects: 83
Study 24021938 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided breathing (12-min sessions daily for 8 weeks)
Number of subjects: 32
Study 24021938 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (including non-pharmacological and pharmacological treatment)
Number of subjects: 32
Study 20007302 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of food folate intake (>= 253.3 microg/d) among women
Number of subjects: 109175
Study 20007302 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of food folate intake (<= 179.1 microg/d) among women
Number of subjects: 109175
Study 20007302 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of food folate intake (>= 229.6 microg/d) among men
Number of subjects: 109175
Study 20007302 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of food folate intake (<= 158.0 microg/d) among men
Number of subjects: 109175
Study 20007302 — intervention group
Group type: EXPERIMENTAL
Intervention: Total folate intake across increasing quartiles among women
Number of subjects: 109175
Study 20007302 — intervention group
Group type: EXPERIMENTAL
Intervention: Total folate intake across increasing quartiles among men
Number of subjects: 109175
Study 18467785 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent acrylic resilient liner denture (RLD)
Number of subjects: 74
Study 18467785 — intervention group
Group type: COMPARATOR
Intervention: Conventional heat‐activated acrylic resin dentures (ARD)
Number of subjects: 74
Study 15892538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nagel anomaloscope
Number of subjects: 79
Study 15892538 — intervention group
Group type: COMPARATOR
Intervention: Holmes‐Wright Type A lantern
Number of subjects: 79
Study 15892538 — intervention group
Group type: COMPARATOR
Intervention: Spectrolux lantern
Number of subjects: 79
Study 15892538 — intervention group
Group type: COMPARATOR
Intervention: Beyne lantern
Number of subjects: 79
Study 15892538 — intervention group
Group type: COMPARATOR
Intervention: Ishihara plates
Number of subjects: 79
Study 12610036 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg, infused daily intravenously for 5 days/week for 14 treatments
Number of subjects: 120
Study 12610036 — intervention group
Group type: COMPARATOR
Intervention: Placebo, infused daily intravenously for 5 days/week for 14 treatments
Number of subjects: 120
Study 12610036 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 120
Study 10608735 — intervention group
Group type: EXPERIMENTAL
Intervention: Latissimus dorsi transfers with neuronal anastomosis
Number of subjects: 12
Study 10608735 — intervention group
Group type: COMPARATOR
Intervention: Latissimus dorsi transfers without neuronal anastomosis
Number of subjects: 12
Study 7731486 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician supervision of the EMS system
Number of subjects: 479
Study 2268574 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin
Number of subjects: 14
Study 2268574 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and gentamicin
Number of subjects: 14
Study 2268574 — intervention group
Group type: EXPERIMENTAL
Intervention: Lincomycin and gentamicin
Number of subjects: 14
Study 2268574 — intervention group
Group type: COMPARATOR
Intervention: Aural toilet alone
Number of subjects: 14
Study 319379 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 10
Study 319379 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined amantadine and haloperidol
Number of subjects: 10
Study 30763527 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-mm lag screws (22 to 26 mm in length)
Number of subjects: 50
Study 30763527 — intervention group
Group type: COMPARATOR
Intervention: 2.0-mm 4-hole miniplates with a gap using monocortical screws
Number of subjects: 50
Study 30763527 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-mm lag screws
Number of subjects: 50
Study 28209359 — intervention group
Group type: EXPERIMENTAL
Intervention: 60mg Fimasartan
Number of subjects: 272
Study 28209359 — intervention group
Group type: EXPERIMENTAL
Intervention: 120mg Fimasartan
Number of subjects: 272